Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of the HSP90 Inhibitor AUY922

This study has been terminated.
(Study halted early due to limited response.)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: November 29, 2011
Last updated: November 28, 2016
Last verified: December 2015
Results First Received: November 28, 2016  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma
Intervention: Drug: AUY922

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: August 28, 2016 to June 17, 2014. All recruitment done at The University of Texas MD Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 26 participants screened for enrollment, five were not eligible therefore excluded from the study before any treatment assignment.

Reporting Groups
AUY922 AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.

Participant Flow:   Overall Study
Withdrawal by Subject                3 
Adverse Event                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
AUY922 AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (33 to 77) 
[Units: Participants]
Count of Participants
Female      5  23.8% 
Male      16  76.2% 
Race/Ethnicity, Customized 
[Units: Participants]
Count of Participants
Asian   1 
Black   1 
Hispanic   13 
White   15 
Region of Enrollment 
[Units: Participants]
United States   21 
Baseline Lymphoma Diagnosis [1] 
[Units: Participants]
Count of Participants
DLBCL   14 
PTCL   6 
Unknown   1 
[1] Histologically confirmed participant diagnosis at baseline by Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL)

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Objective Response in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) and Peripheral T-cell Lymphoma (PTCL)   [ Time Frame: 56 days ]

2.  Primary:   Overall Response Rate (ORR)   [ Time Frame: Up to 12 cycles or 48 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Although the study surpassed the first futility endpoint for DLBCL cohort, it was terminated early due to limited responses and significant toxicities witnessed in the entire cohort of the study.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Yasuhiro Oki, Associate Professor, Lymphoma/Myeloma
Organization: The University of Texas (UT) MD Anderson Cancer Center
phone: 713-792-7734

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01485536     History of Changes
Other Study ID Numbers: 2011-0467
NCI-2012-00070 ( Registry Identifier: NCI CTRP )
Study First Received: November 29, 2011
Results First Received: November 28, 2016
Last Updated: November 28, 2016